Orphan Drug Launch Monitor (ODLM): H82-27/2016-PDF
Observateur des médicaments orphelins (OMO).
"To stimulate drug development, a number of countries have adopted orphan drug regulatory frameworks. These include the United States (US) (1983), Singapore (1991), Japan (1993), Australia (1997), the European Union (EU) (1999/2000), Taiwan (2000) and South Korea (2003). The Orphan Drug Launch Monitor analyzes the international approval of designated orphan drugs and assesses their availability in Canada. This analysis focuses on a number of select orphan drugs reported at the active-substance level and identified based on the following criteria: drugs that received orphan designation and approval in the US and/or EU over the last decade (2005–2014); and drugs that only have orphan indications. The international market analyzed includes Canada and the seven PMPRB comparator countries (PMPRB7): France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the US. The results report on sales and prices for 2014. Based on the selection criteria, 134 orphan drugs were identified, accounting for 2.9% of the international pharmaceutical sales in 2014"--Background and approach.
|Department/Agency||Patented Medicine Prices Review Board.|
|Title||Orphan Drug Launch Monitor (ODLM)|
|Subtitle||Observateur des médicaments orphelins (OMO).|
|Language||Bilingual-[English | French]|
|Electronic Document|| |
Note: The URLs contained in this/these document(s) may no longer be functional
|Note||Caption title. At head of title: National Prescription Drug Utilization Information System.|
|Number of Pages|| p. :|
|Subject Terms||Drugs, Pharmaceutical industry, Government policy|
- Date modified: